Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

NCT ID: NCT01296035

Last Updated: 2015-08-25

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-02-28
• Study Completion Date: 2013-11-30

Brief Summary

This is a study to find out if the study drug, panitumumab, when given with gemcitabine works in treating ovarian cancer and to find out what side effects occur when they are given together.

Detailed Description

Epithelial ovarian cancer (EOC) remains a leading cause of gynecologic cancer mortality in women, with more than 22,000 deaths per year in the United States alone. Due to the lack of effective screening strategies and subtle early symptoms, eighty percent of newly diagnosed patients have disease that is advanced. Despite cytoreductive surgery and adjuvant paclitaxel-based and platinum-based chemotherapy, 5-year survival rates continue to be less than 40%. For patients who become resistant to the platinum compounds (defined as progressive disease while on a platinum-based chemotherapy regimen (refractory) or within 6 months of completing a platinum-based chemotherapy regimen (resistant)),the outlook is particularly poor, and often heralds multi-drug resistant disease.

At the present time, the management of ovarian cancer in the platinum refractory disease state is limited to palliative intent. Patients with advanced, bulky tumors, poor performance status and nutritional compromise are unlikely to respond to therapy and may be best served by supportive care. The clinical management of refractory disease requires both patience and persistence. A patient with platinum refractory disease is begun on one of the agents with activity and an evaluation of response is made every 6-8 weeks of therapy. As long as the patient shows no signs of disease progression, the therapy can be continued unless there is unacceptable toxicity. When progressive disease is observed, another of the list of available agents can be used. It is likely that patients will receive multiple single agents during the chronic phase of their illness. Every effort should be made to balance disease response with toxicity and quality of life.

Based on this rational, this trial will be conducted to evaluate the safety and efficacy of panitumumab, a human antibody targeted to the EGF-R, and Gemcitabine, in treating women with recurrent platinum-refractory/resistant EOC. Our aim is to determine the safety and feasibility of gemcitabine and panitumumab therapy in this population and once completed, to proceed with an efficacy study using an expanded cohort.

Conditions

Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Panitumumab and Gemcitabine

Panitumumab and Gemcitabine

Group Type: EXPERIMENTAL

Panitumumab

Intervention Type: BIOLOGICAL

Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.

Interventions

Panitumumab

Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed diagnosis of metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.
• Prior first line therapy with a platinum and taxane based combination as adjuvant therapy
• Measurable disease defined by RECIST criteria
• Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
• Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
• age > 18
• Karnofsky performance status > 70
• Up to three prior lines of cytotoxic therapy in the setting of recurrent disease.
• Estimated life expectancy of at least 3 months
• Women of child-bearing potential must have a negative pregnancy test
• Adequate hematopoietic function defined as:

• ANC ≥ 1500/mm3
• Platelets ≥ 100,000/mm3
• Hemoglobin ≥ 9 g/dL
• Magnesium ≥ lower limit of normal
• Calcium ≥ lower limit of normal
• Adequate renal and hepatic function defined as:

• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• SGOT ≤ 3 times ULN
• Alanine aminotransferase (ALT) ≤3xULN (if liver metastases ≤5xULN)
• Alkaline phosphatase ≤ 3 times ULN
• Creatinine ≤ 1.5 mg/dL times ULN
• Creatinine clearance ≤ 50 mL/min

Exclusion Criteria

• Prior anti-EGFr antibody therapy (e.g., cetuximab) or treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib, lapatinib)
• Prior treatment with gemcitabine
• Radiotherapy ≤ 14 days prior to enrollment.
• More than three lines of systemic chemotherapy for recurrent or advanced disease. Prior hormonal therapy is allowed.
• Prior immunotherapy, or experimental or approved proteins/antibodies
• Female subject is pregnant or breast-feeding.
• Patient has received other investigational drugs within 28 days before enrollment
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
• Prior treatment with panitumumab
• Concurrent uncontrolled illness
• Ongoing or active infection
• History or active secondary cancer within the last 5 years, except for superficial basal cell skin cancers, curatively resected non-melanoma skin cancer
• Psychiatric illness or social situation that would preclude study compliance.
• History or known presence of central nervous system (CNS) metastasis
• Subjects requiring chronic use of immunosuppressive agents (e.g., methotrexate, cyclosporine)
• Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) < 1 year before randomization
• History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or any evidence of interstitial lung disease on baseline chest CT scan
• Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
• Major surgery within 28 days or minor surgery within 14 days of study enrollment

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Amgen

INDUSTRY

Sponsor Role: collaborator

Women and Infants Hospital of Rhode Island

OTHER

Sponsor Role: lead

Responsible Party

Carolyn McCourt

Dr. Carolyn McCourt

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Carolyn McCourt, MD

Role: PRINCIPAL_INVESTIGATOR

Women & Infants' Hospital

Locations

Women & Infants' Hospital

Providence, Rhode Island, United States

Countries

United States

Other Identifiers

WIH 20050782

Identifier Type: -

Identifier Source: org_study_id